Rua Bioscience NZX:RUA:
SALES FOR Q1 FY26 ARE A RECORD
RENOUCENABLE RIGHTS ISSUE OF 1 NEW SHARES FOR EVERY 3 EXISTING SHARES TO RAISE UP TO NZ$2MILLION
ISSUE PRICE UNDER RIGHTS OFFER NZ$0.025 PER SHARE
Rua Bioscience Says Sales For Q1 FY26 Are A Record
Story so far
Earlier from Rua Bioscience
- RUA: Revenue surged, losses narrowed, and a capital raise is planned to fund further growth
- RUA: FY25 revenue soared and losses narrowed, but further capital is needed to fuel global growth
- Rua Bioscience Says Co & Cann Reach Resolution In Legal Proceedings
- RUA: Revenue growth and narrowed loss offset by ongoing liquidity and going concern risks
- RUA: FY24 saw revenue growth, capital needs, and global expansion plans for Rua Bioscience
Later from Rua Bioscience
- NZ's Rua Bioscience falls to over three-month low on discounted capital raising
- Rua Bioscience Secures New Long-Term Supply Arrangement In Germany
- Rua Bioscience Secures Exclusive NZ Distribution Rights For Medical Device
- Rua Bioscience Reports Research Partnership To Develop Smoking Cessation Products
- RUA: Revenue surged 92% year-over-year, but losses persist amid ongoing expansion and capital raising
Follow Rua Bioscience into a list and get an email when it puts out news.
Follow Rua Bioscience